肝郁脾虚证模型大鼠血流变及TXB_2、PGFla的变化（英文）

目的：探查中医肝郁脾虚证模型的血流变及相关调节因子的状态。方法：采用慢性束缚应激＋过度疲劳＋饮食失节法建立大鼠肝郁脾虚证模型,测定大鼠造模三周、自然恢复一周时的血流变和血浆TXB2、PGF1a。结果：与正常组相比,模型组大鼠造模三周150/s、38/s、10/s、5/s切变率下的全血粘度、还原粘度均显著升高（P〈0.001）,红细胞聚集指数显著降低（P〈0.001）,红细胞压积显著升高（P〈0.01）,红细胞变形指数无显著性差异（P〉0.05）;血浆TXB2显著升高（P〈0.001）,6-keto-PGF1a显著降低（P〈0.05）,TXB2/PGF1a显著升高（P〈0.01）;模型组大鼠第四周150/s、38/s、10/s、5/s切变率下的全血粘度、还原粘度仍显著升高（P〈0.001或P〈0.01）;红细胞聚集指数显著降低（P〈0.001）;红细胞压积与变形指数无显著性差异（P〉0.05）;血浆TXB2和TXB2/PGF1a显著降低（P〈0.05）,6-keto-PGF1a显著升高（P〈0.05）。结论：肝郁脾虚证大鼠存在血液高粘和血栓易形成状态,恢复期血液高粘同时伴有扩血管因素的加强。提示肝郁脾虚证有血流变的异常和血浆TXB2-PGI2的平衡失调,主要涉及到血小板和血浆因素的参与。     

肝郁脾虚证模型大鼠血流变及TXB2、PGF1a的变化

目的:探查中医肝郁脾虚证模型的血流变及相关调节因子的状态。方法:采用慢性束缚应激 过度疲劳 饮食失节法建立大鼠肝郁脾虚证模型,测定大鼠造模三周、自然恢复一周时的血流变和血浆TXB2、PGF1a。结果:与正常组相比,模型组大鼠造模三周150/s、38/s、10/s、5/s切变率下的全血粘度和还原粘度均显著升高(P＜0．001),红细胞聚集指数显著降低(P＜0．001),红细胞压积显著升高(P＜0．01),红细胞变形指数无显著性差异(P＞0．05);血浆TXB2显著升高(P＜0．001),6-keto-PGF1a显著降低(P＜0．05), TXB2/PGF1a显著升高(P＜0．01);模型组大鼠第四周150/s、38/s、10/s、5/s切变率下的全血粘度和还原粘度仍显著升高(P＜0．001或P＜0．01);红细胞聚集指数显著降低(P＜0．001);红细胞压积与变形指数无显著性差异(P＞0．05);血浆TXB2和TXB2/PGF1a显著降低(P＜0．05),6-keto-PGF1a显著升高(P＜0．05)。结论:肝郁脾虚证大鼠存在血液高粘和血栓易形成状态,恢复期血液高粘同时伴有扩血管因素的加强。提示肝郁脾虚证有血流变的异常和血浆TXA2-PGI2的平衡失调,主要涉及到血小板和血浆因素的参与。     

黄芪丹参不同配伍对气虚血瘀模型大鼠血液流变学和血管内皮因子的影响

目的:研究黄芪丹参不同配伍对气虚血瘀证大鼠血液流变学和血管内皮因子的影响。方法:将SD大鼠随机分为对照组、模型组、丹参组、黄芪组、黄芪丹参1:1组、2:1组、4:1组,采用限食、游泳、皮下注射肾上腺素方法建立气虚血瘀证大鼠模型,对照组与模型组给予蒸馏水,用药组分别给予不同剂量的丹参、黄芪及不同比例黄芪丹参配伍灌胃给药治疗,连续27日。测定血液流变学指标,内皮素-1(ET-1)、一氧化氮(NO)、血栓素B2(TXB2)和6-酮-前列腺素-F1α(6-keto-PGF1α)含量。结果:模型组大鼠血液流变学参数和血管内皮因子与对照组比较,差异具有统计学意义(P0.01)。与模型组比较,黄芪丹参1:1组、2:1组、4:1组血液流变学参数显著降低(P0.05或P0.01),NO、6-keto-PGF1α、6-keto-PGF1α/TXB2明显升高(P0.01),ET-1、TXB2明显降低(P0.01)。与1:1组比较,2:1组血液流变学参数显著下降(P0.05或P0.01),NO、6-keto-PGF1α、6-keto-PGF1α/TXB2显著升高(P0.05或P0.01),TXB2明显降低(P0.05)。2:1组大鼠血液流变学参数和血管内皮因子与4:1组比较,差异具有统计学意义(P0.05或P0.01)。结论:黄芪丹参配伍对气虚血瘀证大鼠模型具有改善血液流变及保护血管内皮作用,其中以黄芪丹参2:1组最佳。     

二种血瘀证动物模型内皮功能及血液流变学的比较

目的通过对二种血瘀证大鼠模型的内皮素（ET）、一氧化氮（NO）和血液流变学指标进行比较,探讨其在血瘀证量化诊断中的意义。方法SD大鼠50只,分别建立气虚血瘀证和气滞寒凝血瘀证动物模型,测定二种模型血浆ET和NO水平,用LBY-N6B全自动自清洗血流变仪对二种模型进行血液流变学的分析。结果（1）与模型对照组比较,气虚血瘀模型组全血黏度低切变率、毛细管血浆黏度均明显增加（分别为P〈0.05）,血浆ET水平显著升高（P〈0.01）,NO水平显著降低（P〈0.01）;（2）与空白对照组比较,气滞寒凝血瘀模型组全血黏度低切、中切、高切以及毛细管血浆黏度均明显增加（分别为P〈0.01）,红细胞聚集指数增加（P〈0.05）,血浆ET水平显著升高（P〈0.01）,NO水平显著降低（P〈0.01）。结论内皮细胞损伤,ET和NO比例失衡可能是血瘀证量化诊断的重要指标。     

葛根素对肺心病大鼠血液流变学和肺动脉压的影响

目的:观察葛根素对肺心病大鼠血液流变学和肺动脉压的影响。方法:40只SD大鼠随机分为4组(n=10):对照组,模型组,葛根素低剂量(300 mg/kg ip)和高剂量组(600 mg/kg ip),参考薛氏常压低氧方法建立肺心病大鼠模型,常压低氧4周后测定大鼠血浆粘度,全血粘度,红细胞容积,纤维蛋白原和红细胞聚集指数等血液流变学指标和平均肺动脉压。结果:葛根素能显著降低肺心病大鼠血浆粘度,全血粘度,红细胞容积,纤维蛋白原(P<0.05),对红细胞聚集指数无显著性作用(P>0.05),显著降低模型组降低肺动脉压(P<0.05)。结论:葛根素对肺心病大鼠有治疗效果,为临床治疗肺心病提供实验依据。     

红花注射液对慢性低O2高CO2肺动脉高压的影响

目的：探讨红花注射液对大鼠在慢性低O2高CO2下肺动脉高压的抑制作用。方法：将SD大鼠分为对照组,慢性低O2高CO2组,慢性低O2高CO2＋红花注射液组。用电镜、放免等方法,观察各组大鼠肺动脉平均压、颈动脉平均压、肺细小动脉显微结构、血浆和肺匀浆TXB2及6-keto-PGF1a含量的变化。结果：①慢性低O2高CO2组mPAP比对照组显著增高,红花注射液组的mPAP比慢性低O2高CO2组显著降低,3组间mCAP比较差异无显著性。②慢性低O2高CO2组与对照组相比血浆和肺匀浆TXB2浓度、TXB2／6-keto-PGF1a比值显著增高,6-keto-PGF1a浓度显著下降;红花注射液组与慢性低P2高CO2相比血浆和肺匀浆TXB2浓度、TXB2／6-keto-PGF1a显著下降,6-keto-PGF1a显著升高。③光镜下慢性低O2高CO2组与对照组相比,肺细小动脉管壁面积／管总面积（WA／TA）和肺细小动脉中膜厚度（PAMT）均显著增高。红花注射液组WA／TA和PAMT显著降低。④电镜下慢性低O2高CO2组大鼠肺细小动脉内皮细胞吞饮小泡增多,血管壁增厚,中膜平滑肌细胞增生,纤维细胞增多,肺泡Ⅱ型上皮细胞微绒毛脱落;红花注射液组肺细小动脉中膜平滑肌细胞增生减轻,纤维细胞少,胶原纤维减少,肺泡Ⅱ型上皮细胞微绒毛丰富、结构清。结论：红花注射液有减轻慢性低O2高CO2性肺动脉高压和肺血管结构重建的作用,可能与抑制TXA2的合成,保护血管内皮细胞,使TXA2/PGI2比值降低有关.     

大鼠肝癌诱发过程中血粘度及红细胞变形能力的异常改变

为了全面地反映肝癌发生发展整个过程的血液流变性的异常,本实验采用二乙基亚硝胺诱发大鼠肝癌模型,分六个相检测五个切变率下的全血粘度、血浆粘度及红细胞变形能力。结果表明红细胞变形能力随着肿瘤发展逐渐减低,血浆粘度随着诱癌时间延长 渐升高,到肿瘤晚期趋于平缓,而全血粘度先是升高,到诱癌２０周以后反而有下降趋势。     

塞来昔布对慢性低O_2高CO_2大鼠肺动脉高压的影响及其机制研究

目的：探讨塞来昔布对慢性低O2高CO2大鼠肺动脉高压的作用。方法：将SD大鼠分为正常对照组,慢性低O2高CO2组,慢性低O2高CO2＋塞来昔布组。用电镜、放免等方法,观察各组大鼠肺动脉平均压、颈动脉平均压、肺细小动脉显微结构、血浆和肺匀浆血栓素B2（TXB2）及6-酮-前列腺素F1α（6-keto-PGF1α）含量的变化。结果：①慢性低O2高CO2组平均肺动脉压（mPAP）比正常组显著升高,塞来昔布组的mPAP比慢性低O2高CO2组显著升高,3组间平均颈动脉压（mCAP）比较差异无显著性。②慢性低O2高CO2组与正常对照组相比血浆和肺匀浆TXB2浓度、TXB2/6-keto-PGF1α比值显著增高,6-keto-PGF1α浓度显著下降;塞来昔布组与慢性低O2高CO2组相比血浆和肺匀浆TXB2浓度无明显变化、TXB2/6-keto-PGF1α显著升高,6-keto-PGF1α显著下降。③光镜下慢性低O2高CO2组与正常组相比,肺细小动脉管壁面积/管总面积（WA/TA）和肺细小动脉中膜厚度（PAMT）均显著增高。塞来昔布组与慢性低O2高CO2组相比WA/TA和PAMT显著增高。④电镜下慢性低O2高CO2组大鼠肺细小动脉内皮细胞吞饮小泡增多,血管壁增厚,中膜平滑肌细胞增生,纤维细胞增多,肺泡II型上皮细胞微绒毛脱落;塞来昔布组中膜平滑肌细胞增大、增多,胞浆肌丝丰富,平滑肌细胞间隙增宽,肺泡隔胶原纤维增生明显。结论：塞来昔布可能有加重慢性低O2高CO2性肺动脉高压和肺血管结构重建倾向,过度抑制COX-2,使TXA2/PGI2比值升高可能是其作用机制之一。     

大鼠脑缺血-再灌注前后血浆TXB2及6-Keto-PGF1α含量的变化

目的:本实验旨在揭示脑缺血-再灌注损伤前后大鼠血浆血栓素B2(TXB2)及6-酮前列腺环素F1(6-Keto-PGF1α)的动态变化.方法:制作脑缺血-再灌注大鼠模型,45只健康SD大鼠随机分为正常对照组、模型组和假手术组大鼠.在术后1天、3天、5天和7天分别观察大鼠血浆TXB2和6-Keto-PGF1α含量.结果:线栓大脑中动脉后造成脑缺血,血浆TXB2含量和TXB2/6-Keto-PGF1α比值明显高于假手术组和正常对照组(p＜0.05或0.01),在缺血第1天最显著.结论:脑缺血-再灌注损伤后,血浆TXB2和TXB2/6-Keto-PGF1α的变化规律可为临床缺血性脑损伤治疗提供重要参考.     

大鼠肢体缺血/再灌注后的心肌损伤和NO的保护效应

目的:探讨大鼠肢体缺血/再灌注(LI/R)后心肌的损伤性变化及NO的保护效应。方法:制备LI/R动物模型,将Wistar大鼠随机分为4组(n=10):C(control)组、I/R组、L-Arg组和L-NAME组。用生物化学方法测定大鼠血浆CK、CK-MB及NO水平,测定心肌组织XOD、SOD、MDA含量。用BL-420生物机能实验系统监测大鼠MAP、LVSP、±dp/dtmax等。结果:LI/R后,血浆CK、CK-MB水平均明显升高(P<0.01);心肌组织SOD活性降低而MDA、XOD含量增加(P<0.01或P<0.05);MAP、LVSP、dp/dtmax、-dp/dtmax均降低(P<0.01或P<0.05);血浆NO水平在L-Arg组明显升高(P<0.01),在L-NAME组显著降低(P<0.05)。结论:大鼠LI/R可引起心肌损伤,机体的氧化应激状态可能是其发生机制之一;提高体内NO水平可在一定程度上减轻LI/R后心肌损伤的程度。     

Pancreas prostanoid production in ischemia and reperfusion.

This study was carried out to investigate the proportion of the 6-keto prostaglandin F1 alpha (6-keto PGF1 alpha) and thromboxane B2 (TXB2) alteration that is due to ischemia in pancreas transplantation against the proportion due to reperfusion. For this purpose, Lewis rats were divided in three experimental groups: Group I = Control, Group II = Donor pancreas subjected to 15 minutes of cold ischemia, Group III = Same as group II but pancreas were transplanted to the recipient individual and then subjected to reperfusion. The results indicate that increases in pancreas 6-keto PGF1 alpha occur as a consequence of cold ischemia while TXB2 remains unchanged. When blood flow was restored, 6-keto PGF1 alpha remained unchanged compared to the ischemic group while pancreatic levels of TXB2 were significantly increased. These results suggest a different induction of prostanoid metabolism during ischemia and reperfusion in pancreatic tissue.     

Effects of nitrogen dioxide exposure on the contents of prostaglandins and thromboxane B2 in broncho alveolar lavage

Effects of 10 ppm nitrogen dioxide (NO2) exposure on the contents of prostaglandins (PGs) and thromboxane (TX) B2 in bronchoalveolar lavage (BAL) of rats were studied. In the BAL of normal rats, the amounts of PGs and TXB2 in the whole lavage were 6-keto-PGF1 alpha (38.0 +/- 6.4 ng) greater than TXB2 (11.8 +/- 4.0 ng) greater than PGF2 alpha (5.7 +/- 1.6 ng) much greater than PGE (0.5 +/- 0.3 ng). Rats were exposed to NO2 for 1,3,5,7 and 14 days. The NO2 exposure decreased in the level of 6-keto-PGF1 alpha by about 35% throughout the exposure. The level of TXB2 was higher in the day 5 exposure group (155%). The contents of PGF2 alpha and PGE first, decreased and then transiently increased on days 3 and 5. PG 15-hydroxy-dehydrogenase activity of lung homogenate decreased correspondingly on day 3 and 5. Then the contents PGF2 alpha and PGE decreased on day 7 and 14. 6-keto-PGF1 alpha and TXB2 are stable metabolites of PGI2, a strong bronchorelaxant and TXA2, a strong bronchoconstrictor respectively. Therefore the results suggested that the decrease in 6-keto-PGF1 alpha, a major prostanoid in the BAL and the increase in TXB2 may correlate with broncho constriction by NO2 exposure.     

Effect of proximal selective vagotomy on gastric prostaglandin content in the Shay-rat ulcer model

During Shay-ulcer formation damages to the barrier of the gastric mucosa develop even before the appearance of macroscopic ulceration. Proximal selective vagotomy prevents these damages. Following pyloric ligation the prostaglandin content of the mucosa changes in parallel with the injuries of the mucosal barrier: TXB2 content of the forestomach increases, while PGF2 alpha content of both the forestomach and the antrum decreases. Following PSV operation the 6-keto-PGF1 alpha content of the mucosa decreases, whereas PGF2 alpha and TXB2 contents exhibit no alteration. As a combined effect of proximal selective vagotomy pretreatment and pyloric ligation the 6-keto-PGF1 alpha and PGF2 alpha contents of the mucosa remain low and the TXB2 increase, otherwise detectable after pyloric ligation, does not take place.     

Zymosan-activated plasma-mediated thromboxane production by the perfused rabbit liver and isolated hepatocytes: involvement of calcium

The present study investigates the mechanism of zymosan-activated plasma (ZAP)-mediated eicosanoid production by the isolated, perfused rabbit liver and described ZAP-mediated eicosanoid stimulation in cultured hepatocytes. Perfused livers receiving untreated plasma demonstrated no significant changes in portal venous pressure or the rates of release of lactic dehydrogenase or acid phosphatase activity (indicators of cellular injury). The control group livers demonstrated stable rates of release for 6-keto PGF1 alpha and thromboxane B2 (TXB2). In contrast, the infusion of ZAP alone resulted in a rapid but transient release of TXB2 from the livers. No significant changes in perfusion pressure or enzyme release were observed following ZAP administration. Perfusion of livers with a calcium-free buffer decreased the basal rates of both 6-keto PGF1 alpha and TXB2 production and significantly, but not completely, attenuated the ZAP-mediated increase in hepatic TXB2 production. Perfusion of livers with nifedipine (3 microM) had no effect on ZAP-mediated TXB2 production in this model. Isolated hepatocytes responded to ZAP-treatment with significant increases in TXB2 production. These data suggest that activated fluid phase complement components induce thromboxane production by specific cells within the liver and that this stimulation is partially dependent upon the release of intracellular calcium but independent of complement-mediated cellular injury.     

Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin

We have used a recently developed enzyme immunoassay (EIA) method for measuring urinary concentrations of TXB2, 6-keto PGF1 alpha, 2,3-dinor-TXB2, 2,3-dinor-6-keto PGF1 alpha and 11-dehydro-TXB2 using acetylcholinesterase from Electrophorus Electricus coupled to TXB2, 6-keto PGF1 alpha and 11-dehydro-TXB2. Urinary PGI2 and TXA2 breakdown products and their metabolites were extracted from 3-40 ml of urine corresponding to 100 mumoles creatinine. Measurements were performed after Sep-Pak extraction and thin layer chromatography separation in a system that allows separation between dinor- and parent derivatives. Because of the relatively high cross reactivity (10-15%) of the anti-TXB2 serum with 2,3-dinor TXB2 and the anti-6-keto PGF1 alpha serum with 2,3-dinor-6-keto PGF1 alpha, measurements were done using 3 antisera (anti-TXB2 and anti-6-keto PGF1 alpha diluted 1/50,000, anti 11-dehydro-TXB2 diluted 1/200,000). The reproducibility of the technique was assessed by measuring the same urine stored frozen in aliquots together with each series of samples (Coefficient of variation 6-12% (n = 20), depending on the compound). In addition, the use of a different solvent system for the thin layer chromatography did not affect the results although the migration of the compounds was modified significantly. Determination of the urinary excretion of TXB2 and prostacyclin metabolites in 17 healthy individuals by this method provided results in agreement with those obtained by other methodologies. In addition, comparisons made between EIA and gas chromatography/mass spectrometry analysis showed good correlation between the urinary metabolites as determined by each technique (r = 0.98).     

Comparison of plasma prostanoid levels in the human cord artery in normal and fetal distressed deliveries

Prostaglandin E2 (PGE2), thromboxane B2 (TXB2; as a stable metabolite of TXA2), prostaglandin F2 alpha (PGF2 alpha) and 6-keto-PGF1 alpha (as a stable end product of prostacyclin) have been measured by using specific radioimmunoassay in the plasma of the cord artery immediately after delivery before the cord was clamped. Plasma prostanoid concentrations in normal deliveries (n = 8, as controls) were 24.8 +/- 2.6 (PGE2), 246.8 +/- 37.0 (TXB2), 122.2 +/- 13.3 (PGF2 alpha) and 82.1 +/- 7.7 (6-keto-PGF1 alpha) respectively (pg/ml, mean +/- s.e). On the other hand, in fetal distressed deliveries showing continuous bradycardia (n = 6), they increased significantly to 275.4 +/- 20.1 (PGE2), 948.6 +/- 102.5 (TXB2), 218.0 +/- 21.4 (PGF2 alpha) and 1498.6 +/- 298.4 (6-keto-PGF1 alpha) respectively (pg/ml, mean +/- s.e, p less than 0.005). However, both PGF2 alpha/PGE2 and TXB2/6-keto-PGF1 alpha ratios declined significantly from 4.70 +/- 0.33 to 0.68 +/- 0.05 and from 3.07 +/- 0.37 to 0.68 +/- 0.12 respectively (mean +/- s.e, p less than 0.005) in the fetal distressed group compared with those of the controls. From these results, it may be concluded that the cord artery, which is known as the patent source for the production of PGE2 and prostacyclin, did exert a sufficiently strong reaction to overcome the undesirable haemodynamic changes to maintain the fetal well-being in utero.     

High glucose levels modulate eicosanoid production in uterine and placental tissue from non-insulin-dependent diabetic rats during late pregnancy

Severe uterine and placental disturbances have been described in diabetes pathology. The relative severity of these changes appears to correlate with high glucose levels in the plasma and incubating environment. In order to characterize changes in eicosanoid production we compared uterine and placental arachidonic acid conversion from control and non-insulin-dependent diabetes mellitus (NIDDM) rats on day 21 of pregnancy, into different prostanoids, namely PGE2, PGF22alpha, TXB2 (indicating the production of TXA2) and 6-keto-PGF1 (indicating the generation of PGI2). PGE2, PGF2alpha and TXB2 production was higher and 6-keto-PGF1alpha was similar in diabetic compared to control uteri. PLA2 activity was found diminished in the NIDDM uteri in comparison to control. A role for PLA2 diminution as a protective mechanism to avoid prostaglandin overproduction in uterine tissue from NIDDM rats is discussed. Placental tissues showed an increment in TXB2 generation and a decrease in 6-keto PGF1alpha level in diabetic rats when compared to control animals. Moreover, when control uterine tissue was incubated in the presence of elevated glucose concentrations (22 mM), similar generation of 6-keto PGF1alpha and elevated production of PGE2, PGF2alpha and TXB2 were found when compared to those incubated with glucose 11 mM. Placental TXB2 production was higher and 6-keto PGF1alpha was lower when control tissues were incubated in the presence of high glucose concentrations. However, high glucose was unable to modify uterine or placental prostanoid production in diabetic rats. We conclude that elevated glucose levels induced an abnormal prostanoid profile in control uteri and placenta, similar to those observed in non-insulin-dependent diabetic tissues.     

Zonal heterogeneity of prostaglandin and thromboxane release in the dog kidney

The release of prostaglandin(PG) and thromboxane(TX) was examined in the six different areas of the normal dog kidney, i.e., renal arterial and venous strips(RA and RV), superficial and deep cortical slices (SC and DC) and outer and inner medullary slices(Om and IM). These tissues were incubated in Krebs-bicarbonate buffer(pH 7.4, 37°C), and the released PGE2, PGF2α, 6-keto-PGF1α and TXB2(as stable metabolites of PG12 and TXA2, respectively) were determined by radioimmunoassay. In RA, RV, SC and DC, 6-keto-PGF1α was predominant, however, there were no quantitative differences between RA and RV, or SC and DC. The release of 6-keto-PGF1α reached a maximum in IM, similar to findings on the release of PGE2 and PGF2α. The release of TXB was uniform in OM and IM. The amount of PGE2, PGF2α, 6-keto-PGF1α and TXB2 released from IM was 2800, 400, 60 and 50 times higher, respectively, than the extent of the release from the cortical slices.These results suggest that PG12 as well as PGE2 and PGF2α, may be involved in renal PG, and that TXA2 is biosynthesized in the normal dog kidney.     

Differential effects of probenecid on the levels of endogenous PGF2 alpha and TXB2 in brain cortex

Probenecid in single or repeated doses does not modify levels of PGF2 alpha and TXB2 in rat brain cortex. After administration of subconvulsant dose of pentamethylene tetrazole (PMT) PGF2 alpha increases sharply and rapidly declines subsequently, whereas the elevation of TXB2 is smaller but of longer duration. After probenecid pretreatment PGF2 alpha levels do not decline up to 30 minutes after the initial peak and are still elevated after 60 minutes. Levels of TXB2 tend to be reduced after pretreatment. Differences in transport process or in biosynthetic compartments for these arachidonic acid (AA) metabolites may account for the observed data.